The world has experienced a dramatic year and the pharmaceutical industry and regulators have been at the forefront of improving the lives of people impacted by the pandemic. The response to the pandemic by the industry and its regulators has been tremendous. Helping solve the world’s problems together has changed the role of the industry and has driven value for the world. In our closing plenary session, we will hear from Joydeep Ganguly, SVP of Gilead, regarding how 2020 redefined the role and the value drivers of their efforts. We will also have Rick Friedman, Deputy Director, Science & Regulatory Policy, Office of Manufacturing Quality, CDER/FDA speak about the advantages of modern manufacturing. The session will conclude with a panel discussion including industry and regulatory leaders.